# PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma

> **NCT03488251** · PHASE2 · TERMINATED · sponsor: **Molecular Templates, Inc.** · enrollment: 8 (actual)

## Conditions studied

- Non-hodgkin Lymphoma,B Cell
- Refractory Diffuse Large B-Cell Lymphoma
- Relapsed Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** MT-3724
- **DRUG:** Gemcitabine
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT03488251
- **Lead sponsor:** Molecular Templates, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-20
- **Primary completion:** 2021-03-12
- **Final completion:** 2021-03-12
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2022-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03488251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03488251, "PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03488251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*